IP Verse

Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Neutral Endopeptidase (Nep) Inhibitor

Patent No. EP3067043 (titled "Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Neutral Endopeptidase (Nep) Inhibitor") was filed by Novartis on Nov 4, 2008. The application was issued on Nov 30, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKAug 30, 2023ELKINGTON AND FIFE
TEVA PHARMACEUTICALSAug 30, 2023D YOUNG
STADA ARZNEIMITTELAug 29, 2023KERNEBECK
BULLE DRAug 28, 2023KUTZENBERGER WOLFF & PARTNER
DR SCHONAug 24, 2023DR SCHON
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBAug 16, 2023SONNENHAUSER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3067043

NOVARTIS
Application Number
EP16157767A
Filing Date
Nov 4, 2008
Status
Granted And Under Opposition
Oct 28, 2022
Publication Date
Nov 30, 2022
External Links
Slate, Register , Google Patents